EGFR-Mediated Chromatin Condensation Protects KRAS-Mutant Cancer Cells against Ionizing Radiation
Authors:
- Meng WangMWMeng Wang
- Ashley M. KernAKAshley M. Kern
- Marieke HülskötterMHMarieke Hülskötter
- Patricia GreningerPGPatricia Greninger
- Anurag SinghASAnurag Singh
- Yunfeng PanYPYunfeng Pan
- Dipanjan ChowdhuryDCDipanjan Chowdhury
- Mechthild KrauseMKMechthild Krause
- Michael BaumannMBMichael Baumann
- Cyril H. BenesCBCyril H. Benes
- Jason A. EfstathiouJEJason A. Efstathiou
- Jeff SettlemanJSJeff Settleman
- 14 May 2014
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 74 (10) , 2825-2834
Abstract
Therapeutics that target the epidermal growth factor receptor (EGFR) can enhance the cytotoxic effects of ionizing radiation (IR). However, predictive genomic biomarkers of this radiosensitization have remained elusive. By screening 40 non–small cell lung cancer cell (NSCLC) lines, we established a surprising positive correlation between the presence of a KRAS mutation and radiosensitization by the EGFR inhibitors erlotinib and cetuximab. EGFR signaling in KRAS-mutant NSCLC cells promotes chromatin condensation in vitro and in vivo, thereby restricting the number of DNA double-strand breaks (DSB) produced by a given dose of IR. Chromatin condensation in interphase cells is characterized by an unexpected mitosis-like colocalization of serine 10 phosphorylation and lysine 9 trimethylation on histone H3. Aurora B promotes this process in a manner that is codependent upon EGFR and protein kinase C α (PKCα). PKCα, in addition to MEK/ERK signaling, is required for the suppression of DSB-inducible premature senescence by EGFR. Blockade of autophagy results in a mutant KRAS-dependent senescence-to-apoptosis switch in cancer cells treated with IR and erlotinib. In conclusion, we identify EGFR as a molecular target to overcome a novel mechanism of radioresistance in KRAS-mutant tumor cells, which stands in contrast to the unresponsiveness of KRAS-mutant cancers to EGFR-directed agents in monotherapy. Our findings may reposition EGFR-targeted agents for combination with DSB-inducing therapies in KRAS-mutant NSCLC. Cancer Res; 74(10); 2825–34. ©2014 AACR.Keywords
All Related Versions
This publication has 52 references indexed in Scilit:
- The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancersNature, 2012
- Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancerNature, 2012
- Systematic identification of genomic markers of drug sensitivity in cancer cellsNature, 2012
- The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivityNature, 2012
- Activated Ras requires autophagy to maintain oxidative metabolism and tumorigenesisGenes & Development, 2011
- Lung Cancer Cell Lines as Tools for Biomedical Discovery and ResearchJNCI: Journal of the National Cancer Institute, 2010
- A Gene Expression Signature Associated with “K-Ras Addiction” Reveals Regulators of EMT and Tumor Cell SurvivalCancer Cell, 2009
- Autophagy mediates the mitotic senescence transitionGenes & Development, 2009
- Biomarkers and Mechanisms of FANCD2 FunctionBioMed Research International, 2008
- Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profilingProceedings of the National Academy of Sciences, 2007